Benjamin M. Parsons

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji Kumar, Susanna Jacobus, Adam D. Cohen et al. · The Lancet Oncology · 2020 · 243 citations · Full text

Hematological Malignancy, Oncology, Marrow Transplantation +11

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Andrew M. Evens, Irene Helenowski, Erika Ramsdale et al. · Blood · 2011 · 158 citations · Full text

Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma

Qing Ye, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Oncotarget · 2015 · 112 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Myc Translocation +15

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

Zijun Y. Xu‐Monette, Ling Li, John C. Byrd et al. · Blood · 2016 · 107 citations · Full text